Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 18/20 | 0.57 |
| ▸ | MEN1 | O00255 | 17/20 | 0.57 |
| ▸ | MAPT | P10636 | 16/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | PKM | P14618 | 10/20 | 0.56 |
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.55 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958677 | 0.83 | SMN1; SMN2 (0.96) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL29951954 | 0.80 | SMN1; SMN2 (0.71) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL1960623 | 0.80 | SMN1; SMN2 (0.71) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL1958069 | 0.77 | ALDH1A1 (0.71) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL20206188 | 0.75 | POLB (0.63) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL3041701 | 0.75 | ALDH1A1 (0.59) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL12964058 | 0.74 | KMT2A (1.00) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL1959071 | 0.74 | POLB (0.61) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL2559210 | 0.73 | ALDH1A1 (0.64) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL15331670 | 0.73 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10920106-B2 | Metal chemical mechanical planarization (CMP) composition and methods therefore | VERSUM MATERIALS US, LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200032107-A1 | Metal Chemical Mechanical Planarization (CMP) Composition And Methods Therefore | VERSUM MATERIALS US, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10465096-B2 | Metal chemical mechanical planarization (CMP) composition and methods therefore | VERSUM MATERIALS US, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1864972-A1 | BCRP/ABCG2 INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | SMN1; SMN2 4177/4885POLB 845/4885ALDH1A1 2424/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | SMN1; SMN2 4030/4885POLB 249/4885ALDH1A1 3670/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | SMN1; SMN2 2078/4885POLB 1637/4885ALDH1A1 1723/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | SMN1; SMN2 4353/4885POLB 2924/4885ALDH1A1 1692/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | SMN1; SMN2 4177/4885POLB 845/4885ALDH1A1 2424/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | SMN1; SMN2 2078/4885POLB 1637/4885ALDH1A1 1723/4885 |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | MCL1, ABL1, FLT3 | SMN1; SMN2 2078/4885POLB 1637/4885ALDH1A1 1723/4885 |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | ABCC1, ABCB1, BRCA1 | SMN1; SMN2 4826/4885POLB 3618/4885ALDH1A1 112/4885 |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | BRD3, BRD2, BRD4 | SMN1; SMN2 4263/4885POLB 660/4885ALDH1A1 4275/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | SMN1; SMN2 4030/4885POLB 249/4885ALDH1A1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.